- $365.45m
- $1.64bn
- $1.08bn
Embecta Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Embecta Reports Q4 and FY 2024 Results, Provides FY 2025 Guidance, Ends Insulin Patch Program
Brief: Embecta Q4 Revenue USD 286.1 Million Vs. IBES Estimate USD 277 Million
U.S. STOCKS ON THE MOVE-Dyne Therapeutics, Maxeon Solar, chip stocks
Embecta rises on US FDA clearance of its insulin patch pump
Brief: embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes
Embecta Corp reports results for the quarter ended in June - Earnings Summary
Brief: Embecta Q3 Revenue USD 272.5 Million Vs. IBES Estimate USD 267.4 Million
Embecta Corp expected to post earnings of 46 cents a share - Earnings Preview
Brief: Diabetes Device Maker Embecta Explores Sale Amid Slowing Profits - FT
Embecta Corp reports results for the quarter ended in March - Earnings Summary
Brief: Embecta Q2 Revenue USD 287.2 Million
Embecta Corp expected to post earnings of 40 cents a share - Earnings Preview
Embecta Corp reports results for the quarter ended in December - Earnings Summary
Brief: Embecta Q1 Revenue USD 277.3 Million
Embecta Corp expected to post earnings of 46 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-ResMed, Revvity, Acuity Brands
U.S. STOCKS ON THE MOVE-Albemarle, Illumina, Eversource Energy
U.S. STOCKS ON THE MOVE-CrowdStrike, Precision BioSciences, Tilray Brands